A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Cannot have received: intratumoural treatment or radiotherapy

Are planning to receive intratumoural treatment or radiotherapy to any of the tumours intended for injection within 28 days prior to Screening, or during treatment with tigilanol tiglate.

Cannot have received: investigational agent or device

Exception: wash-out period of 28 days or 5 half-lives (whichever is shorter) required

Are receiving or have received other investigational agents or have used an investigational device without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate.

Cannot have received: systemic anticancer therapy

Exception: wash-out period of 28 days or 5 half-lives (whichever is shorter) required; patients with ≤ Grade 2 neuropathy may be eligible following discussion with Sponsor Medical Monitor

Are receiving or have received systemic anticancer therapy, without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate.